Pfizer Completes Acquisition of Trillium Therapeutics
On November 17, 2021, Pfizer Inc. announced the successful completion of its acquisition of Trillium Therapeutics, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. This is a great development for Trillium’s foundational technology, based on innovations originating from the lab of Dr. Jayne Danska The Hospital for Sick Children and collaborators at University Health Network. The novel molecule (TTI-621) targets CD47, augmenting the immune system’s ability to destroy cancer stem cells, by overcoming a “don’t eat me” signal.
